Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-453-4 | CAS number: 107-02-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Administrative data
Description of key information
“Acrolein has been found to impair pulmonary antibacterial defense mechanisms upon inhalation exposure in vivo and in vitro.” quotation from European Union Risk Assessment Report Acrylaldehyde (EU, 2001)
However, the studies on this subject “do not suggest that inhaled acrolein causes an immune system effect, but the reduction in removal of bacteria from the alveolar spaces may result from the destruction of functionality of alveolar macrophages present in the respiratory epithelium.” quotation from United States Agency for Toxic Substances and Desease Registry, Toxicological Profile for Acrolein (US ATSDR, 2007)
Key value for chemical safety assessment
Additional information
Acrolein has been the subject of a risk assessment carried out under Community Regulation (EEC) No 793/93 (EU, 2001). The key information on neurotoxicity as stated correspond to the greatest extend to the conclusions on this topic in this assessment and to a further assessments carried out under other international and national programmes published after finalisation of the EU Risk Assessment Report 2001 (United States Agency for Toxic Substances and Desease Registry, Toxicological Profile for Acrolein (US ATSDR, 2007). The information on immuntoxicity of acrolein given in the EU Risk Assessment and the US ATSDR correspond to the greatest extend to further assessments carried out under other international and national programmes published after finalisation of the EU Risk Assessment Report 2001 (World Health Organization, International Programme on Chemical Safety (IPCS), Concise International Chemical Assessment Document of Acrolein, CICADS 43 (WHO, 2002); United States Environmental Protection Agency, Toxicological Review of Acrolein (US-EPA, 2003). In the United States Environmental Protection Agency,
HED Risk Assessment for Reregistration Eligibility Decision (RED) Document for Acrolein (US-EPA, 2008) (US-EPA, 2008), immuntoxicity is not discussed.:
1. European Union Risk Assessment Report of Acrolein (EU, 2001)
“Acrolein has been found to impair pulmonary antibacterial defense mechanisms upon inhalation exposure in vivo and in vitro.” quotation from EU, 2001 p83
“The induction of impairment of the pulmonary antibacterial defense by inhalation exposure to acrolein was observed in studies in mice (Astry and Jakab, 1983; Kawabata and White, 1977) and rats (Carl et al., 1939). Inhalation exposure to 3 or 6 ppm during 8 hours induced a dose dependent impairment of the pulmonary antibacterial defence against infection with Staphylococcus aureusin mice (Astry and Jakab, 1983). Higher concentrations caused increased sensory irritation, but no additional impairment of antibacterial resistance.”
“Suppression of bactericidal activity of pulmonary macrophages was observed in several in vitro studies. Because acrolein is a metabolite of cyclophosphamide, in vitro studies were performed to investigate whether the antitumor activity of cyclophosphamide was mediated by enhanced immune reactivity of acrolein. The results suggest that the immune response is enhanced by acrolein.” quotations from EU, 2001 p79
2. Agreement with further International Reports and Studies Published after Finalisation of the EU Risk Assessment Report 2001
Yes
3. Substantial Disagreements in Comparison to further International Reports to European Union Risk Assessment Report 2001
None
4. Additional Aspects in further International Reports
US ATSDR, 2007 discusses the immunological and lymphoreticular effects of acrolein in more detail: “Short-term exposures to acrolein reduced bactericidal activity of the respiratory tract in experimental animals. Aranyi et al. (1986) observed a significantly lower removal by alveolar macrophages of Klebsiella pneumoniae bacteria from a 3-hour aerosol infection following a 5-day exposure to 0.1 ppm acrolein in mice. No difference was observed in rats for this same exposure/infection protocol (Sherwood et al. 1986). Similarly, 8-hour exposures to 3 and 6 ppm acrolein in mice showed a concentration-related reduction in clearance of Staphylococcus aureus from an 8-hour pulmonary infection. However, exposures to 8–10 ppm did not significantly add to the impairment of bactericidal activity (Astry and Jakab 1983). Rats exposed to 0.55 ppm for 10–26 days had significantly lower numbers of alveolar macrophages, but rats exposed for 60–180 days showed no significant difference in macrophage levels (Bouley et al. 1975). No statistically significant differences in mortality were observed in rats intravenously exposed to Listeria monocytogenes following a 3-week exposure to up to 3 ppm acrolein (Leach et al. 1987). These studies do not suggest that inhaled acrolein causes an immune system effect, but the reduction in removal of bacteria from the alveolar spaces may result from the destruction of functionality of alveolar macrophages present in the respiratory epithelium.” quotation from US ATSDR, 2007, p 39
5. Additional Information in Newer Studies, not Included in the European Union Risk Assessment Report 2001 or further Cited International Reports
None
Justification for classification or non-classification
The available data do not indicate that specific immunotoxicity is an instrinsic activity of acrolein.
Thus, acrolein does not comply with the classification requirements regarding immunotoxicity outlined in regulation (EC) 1272/2008 or the former directive on classification and labelling 67/548/EWG.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.